|
ARB 304
|
ARB 305
|
ARB 336
|
ARB 337
|
BLOCK 1
1:00 – 1:45 pm
|
Melatonin Receptor Agonists for the Prevention of ICU Delirium
Jennifer Voong, Pharm.D.
|
Cefepime for the Treatment of AmpC-producing Enterobacteriaceae
Anna Poston-Blahnik, Pharm.D.
|
Maintenance of opioid use disorder (OUD) using medication-assisted treatment (MAT) in primary care
Matthew Thomas, Pharm.D.
|
Azithromycin for Bronchiolitis Obliterans Syndrome in Lung Transplantation
Felicia Bartlett, Pharm.D.
|
1:45 – 1:55 pm
|
Travel Time to accommodate movement between rooms
|
|||
BLOCK 2
1:55 – 2:40 pm
|
What is the Role for Oral Vasoactive Medications in Decreasing the Duration of IV Vasopressor Therapy?
Lauren Hoth, Pharm.D.
|
Utilization of MRSA Nasal Swabs to Tailor Antibiotic Therapy
Danielle Bozzardi, Pharm.D.
|
Anomalous epilepsy treatment: The role of cannabinoid products in contemporary medicine
Ashley Wellen, Pharm.D.
|
Treatment of Cancer-Associated Venous Thromboembolism
Emily Henningsen, Pharm.D.
|
2:40 – 2:50 pm
|
Travel Time to accommodate movement between rooms
|
|||
BLOCK 3
2:50 – 3:35 pm
|
The Increasing Role of Ketamine Use in Acute and Chronic Pain Management
Cathy Grierson, Pharm.D.
|
An Update on Treatment of Clostridium difficile Infection
Erica Prost, Pharm.D.
|
Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Artificial Heart Valves
Kelly Murphy, Pharm.D.
|
Cyclin 4/6 inhibitors: What is the role of the many drugs and combinations?
Elizabeth Diller, Pharm.D.
|
Date: Oct 9, 2018 01:00 PM - 03:40 PM
Location: Academic & Research Building
CE Hours
Registration closes on Oct 16, 2018 12:00 AM
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Requirements for CE Credit
Registration closes on Oct 16, 2018
at 12:00 AM
Registration Closed
Objectives
- Identify risk factors for delirium and non pharmacologic methods to prevent ICU delirium
- Describe the relationship between melatonin and the sleep-wake cycle
- Evaluate the role of melatonin and melatonin receptor agonists in the prevention of ICU delirium
Speaker(s)/Author(s)
Jennifer Voong, Pharm.D.
|
Activity Number
0033-0000-18-079-L01-PCE Hours
Location
Registration Closed
Objectives
- Identify AmpC resistance in Enterobacteriaceae.
- Describe clinical evidence for the use of cefepime in AmpC-producing Enterobacteriaceae.
Speaker(s)/Author(s)
Anna Poston-Blahnik, Pharm.D.
|
Activity Number
0033-0000-18-075-L01-PCE Hours
Location
Registration Closed
Objectives
- Identify the recommendations for duration of long-term maintenance treatment of opioid use disorder.
- Describe the safety and efficacy of medication-assisted treatment in opioid use disorder.
Speaker(s)/Author(s)
Matthew Thomas, Pharm.D.
|
Activity Number
0033-0000-18-078-L01-PCE Hours
Location
Registration Closed
Objectives
- Define bronchiolitis obliterans syndrome
- Describe the efficacy of azithromycin as treatment and prevention of BOS
Speaker(s)/Author(s)
Felicia Bartlett, Pharm.D.
|
Activity Number
0033-0000-18-065-L01-PCE Hours
Location
Registration Closed
Objectives
- Identify the consequences of prolonged IV vasopressor continuation.
- Define the ideal patient population for initiating oral vasoactive medications.
- Recall appropriate dosing regimens for oral vasoactive medications.
Speaker(s)/Author(s)
Lauren Hoth, Pharm.D.
|
Activity Number
0033-0000-18-076-L01-PCE Hours
Location
Registration Closed
Objectives
- Recommend MRSA nasal screens to guide antibiotic therapy in the patients that would most benefit based on available literature.
- Utilize a patient’s MRSA nasal screen result to guide antibiotic recommendations when appropriate based on treatment indication and clinical context.
Speaker(s)/Author(s)
Danielle Bozzardi, Pharm.D.
|
Activity Number
0033-0000-18-066-L01-PCE Hours
Location
Registration Closed
Objectives
- Evaluate the appropriateness of cannabinoid therapy in epilepsy treatment.
- Describe the regulations required for cannabinoid distribution in Missouri.
Speaker(s)/Author(s)
Ashley Wellen, Pharm.D.
|
Activity Number
0033-0000-18-080-L01-PCE Hours
Location
Registration Closed
Objectives
- Identify factors that increase the risk of cancer-associated venous thromboembolism Identify factors that increase the risk of cancer-associated venous thromboembolism
- Interpret the results of recent trials comparing direct oral anticoagulants with low molecular weight heparins.
- Select an appropriate anticoagulation regimen for a patient with cancer-associated venous thromboembolism.
Speaker(s)/Author(s)
Emily Henningsen, Pharm.D.
|
Activity Number
0033-0000-18-068-L01-PCE Hours
Location
Registration Closed
Objectives
- Identify adverse effects of ketamine.
- Evaluate appropriate use of ketamine in acute pain based on current literature.
- Assess effectiveness of ketamine in the emergency department.
Speaker(s)/Author(s)
Cathy Grierson, Pharm.D.
|
Activity Number
0033-0000-18-073-L01-PCE Hours
Location
Registration Closed
Objectives
- Identify risk factors for developing C. difficile infection.
- Identify appropriate treatment regimens for C. difficile infection.
Speaker(s)/Author(s)
Erica Prost, Pharm.D.
|
Activity Number
0033-0000-18-081-L01-PCE Hours
Location
Registration Closed
Objectives
- Explain the thromboembolic risk associated with artificial heart valves.
- Identify the appropriate use of DOACs in patients with artificial heart valves
Speaker(s)/Author(s)
Kelly Murphy, Pharm.D.
|
Activity Number
0033-0000-18-077-L01-PCE Hours
Location
Registration Closed
Objectives
- Identify the NCCN guideline recommended place in therapy for CDK 4/6 inhibitors.
- Compare and contrast the approved agents within the CDK 4/6 inhibitor class.
Speaker(s)/Author(s)
Elizabeth Diller, Pharm.D.
|